Dupilumab Efficacy in Asthma Patients With FEV1 60-80% Predicted on Medium-Dose ICS: liberty asthma quest Study

被引：1
|
作者：
Papi, Alberto [1 ]
Pavord, Ian D. [2 ]
Fitzgerald, J. Mark [3 ]
Corren, Jonathan [4 ]
Bardin, Philip [5 ,6 ,7 ,8 ]
Park, Hae Sim [9 ]
Rice, Megan S. [10 ]
Deniz, Yamo [11 ]
Rowe, Paul [12 ]
Staudinger, Heribert [12 ]
Amin, Nikhil [11 ]
Ruddy, Marcella [11 ]
Graham, Neil M. H. [11 ]
Teper, Ariel [12 ]
机构：
[1] Univ Hosp Santa Anna, Ferrara, Italy
[2] NIHR Oxford Biomed Res Ctr, Oxford, England
[3] Univ British Columbia, Vancouver, BC, Canada
[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[5] Monash Univ, Melbourne, Vic, Australia
[6] Monash Med Ctr, Melbourne, Vic, Australia
[7] Monash Univ, Clayton, Vic, Australia
[8] Monash Med Ctr, Clayton, Vic, Australia
[9] Ajou Univ, Suwon, South Korea
[10] Sanofi, Cambridge, MA USA
[11] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[12] Sanofi, Bridgewater, MA USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷
关键词：
Asthma; -; management;
D O I：
10.1183/13993003.congress-2019.PA538
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA538
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Dupilumab reduces risk of severe exacerbations and improves FEV1 in patients on both high- and medium dose ICS with uncontrolled, moderate-to-severe asthma from the phase 3 LIBERTY ASTHMA QUEST Study
    Pavord, I
    Papi, A.
    Wenzel, S.
    Park, H.
    Zhang, B.
    Staudinger, H.
    Maroni, J.
    Rowe, P.
    Amin, N.
    Pirozzi, G.
    Ruddy, M.
    Akinlade, B.
    Graham, N. M. H.
    Teper, A.
    ALLERGY, 2018, 73 : 463 - 464
  • [2] Dupilumab Treatment Produces Rapid and Sustained Improvements in FEV1 in Patients with Uncontrolled, Moderate-To-Severe Asthma from the LIBERTY ASTHMA QUEST Study
    Castro, M.
    Busse, W. W.
    Zhang, B.
    Maroni, J.
    Rowe, P.
    Amin, N.
    Pirozzi, G.
    Graham, N. M.
    Teper, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [3] Dupilumab Efficacy in Type 2 Inflammatory Asthma: Liberty Asthma QUEST Study
    Pavord, Ian Douglas
    Fitzgerald, J. Mark
    Brusselle, Guy
    Wenzel, Sally E.
    Rabe, Klaus F.
    Busse, William W.
    Papi, Alberto
    Rice, Megan S.
    Deniz, Yamo
    Rowe, Paul
    Amin, Nikhil
    Graham, Neil M. H.
    Teper, Ariel
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [4] DUPILUMAB EFFICACY IN CHILDREN WITH UNCONTROLLED TYPE 2 ASTHMA ANALYZED BY BASELINE HIGH OR MEDIUM ICS DOSE: LIBERTY ASTHMA VOYAGE STUDY
    Maspero, J. F.
    Antila, M. A.
    Jean, N.
    Deschildre, A.
    Bacharier, L. B.
    Altincatal, A.
    Rimington, T.
    Laws, E.
    Akinlade, B.
    Radwan, A.
    Jacob-Nara, J. A.
    Deniz, Y.
    Rowe, P. J.
    Lederer, D. J.
    Hardin, M.
    THORAX, 2022, 77 : A77 - A78
  • [5] Long-Term Efficacy of Dupilumab in Patients With Asthma With an Allergic Phenotype Rolled Over From LIBERTY ASTHMA QUEST: LIBERTY ASTHMA TRAVERSE Study
    Sher, Lawrence
    Corren, Jonathan
    Pavord, Ian
    Daizadeh, Nadia
    Ortiz, Benjamin
    Djandji, Michel
    Deniz, Yamo
    Rowe, Paul
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB60 - AB60
  • [6] Dupilumab Improved Pre-Bronchodilator FEV1 in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma, Regardless of Presence of Perennial Aeroallergen-Specific IgE: LIBERTY ASTHMA QUEST Study
    Corren, J.
    Jackson, D. J.
    Casale, T. B.
    Daizadeh, N.
    Djandji, M.
    O'Riordan, T.
    Ortiz, B.
    Rowe, P.
    Deniz, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [7] Dupilumab Efficacy in GINA-Defined Difficultto-Treat Type 2 Asthma Patients in the LIBERTY ASTHMA QUEST Study
    Rabe, Klaus
    Mark FitzGerald, J.
    Castro, Mario
    Pavord, Ian
    Maspero, Jorge
    Busse, William
    Daizadeh, Nadia
    Ortiz, Benjamin
    Pandit-Abid, Nami
    Rowe, Paul
    Nikhil, Amin
    Deniz, Yamo
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB59 - AB59
  • [8] Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study
    Tohda, Yuji
    Nakamura, Yoichi
    Fujisawa, Takao
    Ebisawa, Motohiro
    Arima, Kazuhiko
    Miyata, Masanori
    Takahashi, Yoshinori
    Rice, Megan S.
    Deniz, Yamo
    Rowe, Paul
    Patel, Naimish
    Graham, Neil M. H.
    Teper, Ariel
    ALLERGOLOGY INTERNATIONAL, 2020, 69 (04) : 578 - 587
  • [9] Dupilumab Efficacy in LIBERTY ASTHMA QUEST Patients With Uncontrolled, Moderate-to-Severe Asthma By Allergen Sensitization Status
    Corren, Jonathan
    Jackson, David
    Casale, Thomas
    Borish, Larry
    Rabe, Klaus
    Busse, William
    Maspero, Jorge
    Jackson, Daniel
    Daizadeh, Nadia
    Ortiz, Benjamin
    Jacob-Nara, Juby
    Khodzhayev, Angela
    Rowe, Paul
    Djandji, Michel
    Deniz, Yamo
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB15 - AB15
  • [10] Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST
    Pavord, Ian Douglas
    Ford, Linda
    Sher, Lawrence
    Rabe, Klaus F.
    Park, Hae-Sim
    Cosio, Borja G.
    Foster, Meredith C.
    Staudinger, Heribert
    Maroni, Jaman
    Rowe, Paul
    Amin, Nikhil
    Pirozzi, Gianluca
    Ruddy, Marcella
    Akinlade, Bolanale
    Graham, Neil M. H.
    Teper, Ariel
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
12345